Ligand for herpes simplex virus entry mediator and methods of use
AssigneeLa Jolla Institute for Allergy and Immunology
InventorCarl Ware
Life of this patent
Estimating the term…
Abstract
A novel polypeptide ligand, p30, or LIGHT, for herpes virus entry mediator, HVEM, is provided. LIGHT is useful for modulating immune responses and in inhibiting infection and/or subsequent proliferation by herpesvirus. HVEM fusion proteins are also provided. Methods for treating subjects with lymphoid cell disorders, tumors, autoimmune diseases, inflammatory disorders or those having or suspected of having a herpesvirus infection, utilizing p30 and the fusion proteins of the invention, are also provided.
Claims31
A method for treating a subject having a CMV infection comprising contacting the subject with an amount of an agonist antibody or antigen binding fragment thereof that binds to lymphotoxin beta receptor (LTβR) sufficient to treat the CMV infection.
A method for treating a subject having a CMV infection due to immuno suppression or reactivation of CMV from latency, comprising contacting the subject with an amount of an agonist antibody or antigen binding fragment thereof that binds to lymphotoxin beta receptor (LTβR) sufficient to treat CMV infection due to immunosuppression or reactivation of CMV from latency.
Dependencies are inferred from the claim text.